Tenvie Therapeutics, a California-based biotech, announced the dosing of the first subject in a Phase I/Ib clinical study of TNV262, a small molecule NLRP3 inhibitor, in healthy volunteers and adults with obesity. The announcement, made April 6, 2026, marks trial initiation only; no safety, pharmacokinetic, or efficacy data were reported.
The Phase Ia/Ib study is designed as a single and multiple ascending dose evaluation, with primary endpoints covering safety, tolerability, and biomarkers of inflammation and cardiometabolic risk. Secondary endpoints include body weight, body composition, and measures of appetite and eating behavior in participants with obesity. The company said preliminary safety and pharmacokinetic data are expected in the second half of 2026. No dosing details, enrollment targets, or blinding status were disclosed in the announcement.
The trial enrolls healthy volunteers alongside persons with obesity, though the total planned sample size was not stated. No NCT registration number was included in the press release; a registry record had not been publicly indexed at the time of reporting. Tenvie referenced preclinical data showing complete CNS penetrance and suppression of inflammatory cardiovascular risk biomarkers, though the company did not disclose the species, models, or study designs underlying those findings.